Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Weckesser

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
Theranostics|July 21, 2020
Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving <sup>177</sup>Lu-PSMA-617 Radioligand TherapyRobert Seifert, Konstantin Seitzer, Ken Herrmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 16, 2016
Correlation of Intraprostatic Tumor Extent with ⁶⁸Ga-PSMA Distribution in Patients with Prostate CancerKambiz Rahbar, Matthias Weckesser, Sebastian Huss, et al.
Neurosurgery|September 15, 2015
The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular FactorsMohammed Jaber, Johannes Wölfer, Christian Ewelt, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 9, 2025
Prognostic value of [<sup>18</sup>F]FET-PET in diffuse low-grade (grade 2) gliomas after the 2021 classification of CNS tumorsMichael Müther, Lorenz König, Philipp Backhaus, et al.
Theranostics|August 10, 2021
Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapyRobert Seifert, Katharina Kessel, Katrin Schlack, et al.
Epilepsia|September 30, 2005
The prognostic value of [F]FDG-PET in nonrefractory partial epilepsyLars Weitemeyer, Christoph Kellinghaus, Matthias Weckesser, et al.
Transplantation and Cellular Therapy|April 28, 2021
Fluorodeoxyglucose F 18 for the Assessment of Acute Intestinal Graft-versus-Host Disease and Prediction of Response to Immunosuppressive TherapyWolfgang Roll, Georg Evers, Rebecca Strotmann, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|April 17, 2009
Impact of (18)F-FDG-PET/CT on staging and irradiation of patients with locally advanced rectal cancerBrigita Paskeviciute, Tobias Bölling, Markus Brinkmann, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|September 14, 2007
Therapeutic strategies for catatonia in paraneoplastic encephalitisFlorian Kaestner, Christian Mostert, Andreas Behnken, et al.
Neurobiology of Aging|November 7, 2017
Relevance of raised cerebrospinal fluid monocyte levels in patients with frontotemporal dementiaMatthias Pawlowski, Gero Lueg, Catharina C Gross, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
Theranostics|July 21, 2020
Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving <sup>177</sup>Lu-PSMA-617 Radioligand TherapyRobert Seifert, Konstantin Seitzer, Ken Herrmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 16, 2016
Correlation of Intraprostatic Tumor Extent with ⁶⁸Ga-PSMA Distribution in Patients with Prostate CancerKambiz Rahbar, Matthias Weckesser, Sebastian Huss, et al.
Neurosurgery|September 15, 2015
The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular FactorsMohammed Jaber, Johannes Wölfer, Christian Ewelt, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 9, 2025
Prognostic value of [<sup>18</sup>F]FET-PET in diffuse low-grade (grade 2) gliomas after the 2021 classification of CNS tumorsMichael Müther, Lorenz König, Philipp Backhaus, et al.
Theranostics|August 10, 2021
Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapyRobert Seifert, Katharina Kessel, Katrin Schlack, et al.
Epilepsia|September 30, 2005
The prognostic value of [F]FDG-PET in nonrefractory partial epilepsyLars Weitemeyer, Christoph Kellinghaus, Matthias Weckesser, et al.
Transplantation and Cellular Therapy|April 28, 2021
Fluorodeoxyglucose F 18 for the Assessment of Acute Intestinal Graft-versus-Host Disease and Prediction of Response to Immunosuppressive TherapyWolfgang Roll, Georg Evers, Rebecca Strotmann, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|April 17, 2009
Impact of (18)F-FDG-PET/CT on staging and irradiation of patients with locally advanced rectal cancerBrigita Paskeviciute, Tobias Bölling, Markus Brinkmann, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|September 14, 2007
Therapeutic strategies for catatonia in paraneoplastic encephalitisFlorian Kaestner, Christian Mostert, Andreas Behnken, et al.
Neurobiology of Aging|November 7, 2017
Relevance of raised cerebrospinal fluid monocyte levels in patients with frontotemporal dementiaMatthias Pawlowski, Gero Lueg, Catharina C Gross, et al.
Pageof 10